Effect of PF-00734200 in Subjects With Type 2 Diabetes

Pfizer

Status and phase: Completed; Phase 2

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Placebo; Drug: PF-00734200 30 mg QD; Drug: PF-00734200 20 mg QD

Study type: Interventional

Funder types: Industry

Identifiers

NCT00618007

A7941006

Details and patient eligibility

About

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin

Enrollment: 289 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

Exclusion criteria

Type 1 or secondary forms of diabetes Currently using insulin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

289 participants in 3 patient groups, including a placebo group

30 mg QD

Experimental group

Treatment:

Drug: PF-00734200 30 mg QD

20 mg QD

Experimental group

Treatment:

Drug: PF-00734200 20 mg QD

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo